Upgrade to SI Premium - Free Trial

MannKind (MNKD) Risk/Reward More Interesting Ahead of Afrezza Launch, Piper Jaffray Says

November 4, 2014 9:34 AM
Piper Jaffray analyst Joshua Schimmer lowered his price target on Neutral-rated MannKind (NASDAQ: MNKD) to $7.00 (from $9.50) following in-line ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change FDA

Next Articles